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[1] 
Abstract  
Background: Treatment options for patients with glioblastoma at progression have remained 
controversial and selection criteria for the appropriate type of intervention remain poorly defined. 
The objectives were to determine which factors favor the decision for second surgery and which 
factors are associated with overall survival (OS) and to evaluate the NIH recurrent glioblastoma scale.  
The scale includes tumor involvement of eloquent brain regions, functional status and tumor volume.  
Methods: A retrospective single center analysis of patients with newly diagnosed glioblastoma 
undergoing initial surgery between January 2007 and December 2011 was performed. Patients were 
separated into two groups: those with vs. those without second resection surgery at disease 
progression. OS was compared using the multiple logistic regression model, Cox proportional hazard 
regression, and Kaplan-Meier survival analysis. 
Results: The data of 98 patients was statistically analyzed. 58 patients had initial surgery only (age 
61.27y; mOS 14.81 months), 40 patients underwent second surgery at disease progression (age 55y; 
mOS 18.86 months). Age was the only predictor for repeated surgery (P 0.012; odds ratio 0.94. At the 
time of tumor progression, administration of alkylating chemotherapy (P 0.004; HR 0.24) or 
bevacizumab (P 0.001; HR 0.23) was associated with longer OS. Reoperation was associated with a 
lower hazard ratio (P 0.134; HR 0.66). The NIH recurrent glioblastoma scale showed statistically 
significant improvement of prognosis prediction with the addition of age. 
Conclusions: Surgery of progressive glioblastoma and postoperative treatment at the time of 
progression is associated with improved OS in some patients. The addition of age may improve 
survival prediction of the NIH recurrent glioblastoma scale.  
 
[2] 
Introduction 
Over the past decades the prognosis for newly diagnosed glioblastoma has improved only slightly. The 
median survival time is still less than 12 months 14. Standard therapy for newly diagnosed 
glioblastoma comprises maximal safe resection and subsequent radiation therapy with concomitant 
and adjuvant temozolomide 23. At time of progression the standards for clinical intervention are less 
well defined 25. Additional systemic therapy and repeated surgery are commonly considered options. 
Some retrospective studies have focused on the efficacy of second surgery at the time of recurrence. 
However, retrospective studies are limited by selection bias and missing data 1, 3, 6, 8, 9, 12, 18. Prognostic 
factors such as age, Karnofsky performance status (KPS), localization of the tumor and its volume, 
IDH1 mutation status and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation 
status may be taken into consideration 4, 10, 25. Based on a retrospective analysis of 34 patients, Park et 
al. proposed the NIH recurrent glioblastoma scale to preoperatively evaluate the prognostic factors of 
patients with progressive glioblastoma undergoing second surgery 19. Their scale includes three 
factors: tumor involvement of eloquent brain regions, compromised functional status (KPS ≤ 80 %) 
and tumor volume ≥ 50 cm3, thereby dividing the patients into three prognostic subgroups: patients 
with poor, intermediate and good survival. 
The aim of this single center study was to retrospectively analyze the impact of second resection 
surgery at the time of glioblastoma progression in patients exclusively treated in the area of modern 
standard therapy. For this the factors favoring the decision for reoperation and the prognostic factors 
for overall survival (OS) were examined. A secondary goal of the present study was to evaluate the 
NIH recurrent glioblastoma scale with regard to this patient group. 
 
[3] 
Patients and Methods 
Patients 
From January 2007 to December 2011, 341 patients underwent surgery for primary and secondary 
glioblastoma at the University Hospital Zurich. The diagnosis was confirmed histopathologically 
according to the World Health Organization criteria 16. Medical records were reviewed to identify 
patients ≥18 years, diagnosed with glioblastoma, who had undergone MRI resection control within 72 
hours as well as postoperative standard therapy (radiotherapy with concomitant temozolomide and 
at least one cycle of 5/28 temozolomide therapy 23 or if patients were older than 65 years, 
postoperative radiotherapy with 40 gy 13, 20. The time of progression or recurrence (in the text labeled 
progression for simplification) was assessed in all patients and validated by contrast-enhancing mass 
on T1-weigted magnetic resonance imaging (MRI). At this point the findings were discussed at an 
interdisciplinary tumor board including four different surgeons. Patients with initially lower grade 
gliomas, infratentorial tumor location, younger than 18 years or without MRI confirmed progression 
were excluded. 
In total, 98 patients met our inclusion criteria (Fig. 1). Of these, 40 underwent a second, maximal safe 
surgical resection and further neurooncological treatment at time of progression, defined as “study 
group A”. The control group consisted of 58 patients without additional surgery, but further 
treatment at progression, defined as “group B”. 
 
Variables and goals 
Medical records were reviewed with regards to age, gender, tumor volume (ellipsoid: 
4/3*π*x*y*z/2), tumor localization, number of eloquent brain regions involved: presumed motor 
[4] 
area, presumed speech area, areas directly adjacent to the M1 and/or M2 segments of the middle 
cerebral artery (equivalent to the motor-speech-middle cerebral artery (MSM) score, introduced by 
Park et al. 19), four categories of symptoms (motor, speech, vision, neuropsychological deficits), NIH 
recurrent glioblastoma scale (Table 1), KPS, and preoperative need of steroids. In addition, the Ki-67 
labeling index and MGMT promoter methylation status detected by methylation-specific PCR were 
documented. Contrast T1-weighted MRI images from before and immediately after resection were 
used to quantify the extent of resection: >95% gross total resection (GTR), ≤ 95% subtotal resection 
(STR) and biopsy 4, 21. A detailed history of the therapeutic modalities was recorded. IDH1 status was 
identified by immunohistochemical staining for the study group A (Table 2). The primary objective of 
this retrospective analysis was to define (i) factors at disease progression associated with the 
subsequent decision for reoperation, (ii) prognostic factors for OS and (iii) to validate the NIH 
recurrent glioblastoma scale. The study was approved by the local ethic committee (KEK-ZH-Nr. 2012-
0257). 
Statistics  
Baseline characteristics are shown as median and interquartile range for continuous variables and as 
numbers and percentages of the total for categorical variables. The statistical analysis was a two-step 
procedure. In the first step, a multiple logistic regression model was fit to the dependent variable 
recurrent resection (1=yes, 0=no), with age at diagnosis, preoperative KPS (1st surgery), tumor 
volume (1st surgery) and tumor location (1st surgery), and time from diagnosis to progression as 
predictor variables. The results are presented as odds ratios (OR). In a second step, a Cox proportional 
hazards model was fit to OS time, with independent variables regarding time to progression: age at 
time of diagnosis, post-second surgery temozolomide, lomustine or bevacizumab, recurrent resection 
and tumor localization. When we evaluated the NIH recurrent glioblastoma scale (Table 1), the 
[5] 
dependent time variable was calculated as time from second surgery to death. To calculate the NIH 
recurrent glioblastoma scale, data from the second surgery was used. The estimated effects from the 
Cox models are presented as hazard ratios (HR). All analyses were performed with R programming 
(Team RDC, Vienna, Austria). 
 
Results 
Patients 
In total 98 patients were included in this analysis. The study group A consisted of 40 patients (mean 
age 55, SD 8.33), 29 males and 11 females. At initial surgery 30 patients underwent GTR and 10 
patients STR. At second surgery 27 patients had GTR and 13 STR. After the second surgery 8 patients 
received temozolomide postoperatively, two patients were treated with lomustine, 28 patients with 
bevacizumab and 2 patients received no postoperative therapy (Table 2). 
The control group (B) consisted of 58 patients (mean age 61, SD 11.20), 35 males and 23 females. Of 
these, 39 patients had GTR and 14 STR. 5 patients underwent a biopsy at initial surgery. At 
progression, 8 patients received temozolomide, 1 patient lomustine, 38 patients bevacizumab and 11 
received no systemic therapy. By definition, no patient of group B had second surgery at disease 
progression. The initial median KPS score was 80 % for both groups (Table 2). 
Variables that determine repeated surgery at time of progression 
After combining the study group (group A) with the reference group (group B), a logistic regression 
model with the dependent variable of recurrent surgery was used. As shown in table 3, only age was 
significantly associated with recurrent surgery (odds ratio=0.944; 95% CI 0.902-0.987; p=0.012); 
preoperative KPS, tumor volume and the time period between diagnosis and recurrence were not 
significant (Table 3). 
[6] 
  
Prognostic variables for post-progression survival 
At the time of progression, the Cox proportional hazards model resulted in a statistically significant 
association of systemic treatment with temozolomide or lomustine (HR=0.240, 95% CI 0.091-0.637, 
p=0.004) and bevacizumab (HR=0.235, 95% CI 0.099-0.557, p=0.001) and OS. For these two variables a 
protective effect was recognized in terms of a HR considerably smaller than 1. The significance is 
limited because only two patient had no alkylating therapy at progression. The HR rises with 
increasing age (10 % significance level). The estimated HR for repeated resection (HR=0.664; 95% CI 
0.389-1.134; p=0.134) and age at diagnosis (HR=1.025, 95% CI 0.997-1.055, p=0.085) were not 
statistically significant. 
 
Evaluation of the NIH recurrent glioblastoma scale 
Applying the NIH recurrent glioblastoma scale to our patient series scored 20 patients with 0 points, 
16 patients with one point and four patients with two points. These correspond to the following NIH 
prognostic groups: good (score value = 0) 20 patients, intermediate (score values = 1 or 2) 20 patients, 
and poor (score value =3) none. The median postoperative survival was 8.33 months (SD 1.01; 95% CI 
5.93 to 13.1) in the intermediate category and 13.93 months (SD 1.23; lower 95% CI 11.48) in the 
good category, respectively (Fig. 2). The distinction was statistically significant (HR 2.526, 95% CI 1.207 
to 5.287).  
 
 
 
[7] 
Improvement proposal for the NIH recurrent glioblastoma scale 
Three models for amending the NIH recurrent glioblastoma scale were examined: (1) NIH + residual 
tumor at initial surgery, (2) NIH + postoperative complications after initial surgery, and (3) NIH + age 
at initial diagnosis. The examined models were based on variables, that were of known prognostic 
relevance and available at time of progression. Cox proportional hazards models for OS after 
recurrent surgery were used to explore the three additional variables. As a result, only the addition of 
the age at initial diagnosis (dichotomized with cut off ≥ / < 50 years) resulted in an independent and 
significant refinement of the existing score. The Cox model with age and NIH recurrent glioblastoma 
scale resulted in a HR=3.972 (95% CI 1.681-9.382, p=0.002). 
Having established the independent effect of age, we propose to update the NIH recurrent 
glioblastoma scale accordingly. In order to evaluate the single effects of the four predictors of the 
scale, namely KPS, tumor volume, motor-speech-middle cerebral artery score and age, we applied a 
Cox model to the four predictors. The resulting estimated HRs were 2.372 (KPS ≤ 80), 17.049 (tumor 
volume ≥ 50), 4.110 (MSM ≥ 2) and 4.142 (age ≥ 50). Therefore, we recommend assigning one point 
for KPS ≤ 80 %, MSM ≥ 2 and age ≥ 50, and two points for tumor volume ≥ 50 (Table 1). Accordingly, 
the new scale ranges from 0-5. Applying the new scale to the present data, results in eight patients 
with zero points, 17 patients with one point, 12 patients with two points, zero patients with three 
points and three patients with four points. Again, it is desirable to distinguish between patients with a 
good, an intermediate or a poor prognosis. For this reason, the Kaplan-Meier curves of the separate 
score values were considered (Fig. 2). Based on this analysis we suggest that patients with score = 0 
are considered to have a good prognosis, with score = 1 or 2 an intermediate and with a score ≥ 3 a 
poor prognosis (Table 1). 
 
[8] 
 [9] 
Discussion 
Treatment modalities of patients with glioblastoma at time of progression are variable and remain 
controversial 1, 3, 7, 9, 12, 25. Studies often show bias because of insufficient data regarding the efficacy of 
treatment modalities after resection of recurrent glioblastoma. Direct comparison between data 
published before 2005 and after is limited due to the change in paradigm for firstline therapy 14, 15, 24. 
Furthermore, additional data has accumulated with the advent of bevacizumab in 2009 and its partial 
implementation into treatment protocols 15, 25. 
 
To evaluate which factor determines a second surgery, a logistic regression analysis was performed. 
The results revealed that younger age was the only significant predictor for repeated surgery. No 
other factors, e.g. preoperative KPS, tumor volume and tumor location were predictive for the 
decision for reoperation. This is in line with the results described earlier by Helseth et al. 2010, who 
reported that primarily younger patients undergo repeated surgery 12. It is interesting to note that a 
consistent clinical selection bias in series of 2nd surgery is age.  
In addition, this study tries to analyze the influence of repeated surgery followed by postoperative 
systemic therapy in glioblastoma patients. The Cox proportional hazards model revealed an 
association of postoperative systemic treatment after 2nd surgery and OS. Whether systemic 
treatment after second surgery definitively leads to a better outcome in patients with progressive 
glioblastoma, warrants further investigations.  Second surgery as such was not statistically significant 
in this model, but the hazard ratio implied a trend towards improved OS, which may become 
significant in a larger dataset. Some studies showed a longer OS for patients with second surgery 6, 12, 
22, whereas Clark et al. 2011 described no significant effect with regards to the 6 months progression-
free survival in the re-operated versus not operated group 7. These results suggest that a careful 
[10] 
patient selection at the time of progression is compulsory in order to improve their OS on the basis of 
the as aforementioned measures.  
 
Validation and refinement of the NIH recurrent glioblastoma scale 
To our knowledge, the present analysis is the first trial to validate the NIH recurrent glioblastoma 
scale published by Park et al. in 2010. The distinction between the prognostic groups was statistical 
significant in our dataset. Several studies have described the significant influence of age as a 
prognostic factor for primary glioblastoma 5, 11, 19, 26. However, age was not considered in the NIH 
recurrent glioblastoma scale. In the present analyses we identified age with a cut off ≥ 50 years as an 
additional significant prognostic factor (Fig. 2). This study does not demonstrate that the prognostic 
groups depend on resurgery. However, the modified NIH scale seems to improve the predictive 
strength of the prognostic groups for OS. This may prove to be a useful clinical decision tool before 
considering 2nd surgery. 
 
Limitations and need of a prospective randomized trial  
The appraisal of repeated surgery and postoperative treatment after 2nd surgery on OS survival is 
difficult for various reasons. First, just as in the present study, data in the literature is derived mostly 
from retrospective analyses. Second, bias regarding inclusion criteria, patient selection and treatment 
protocols exist. To limit these factors, we included only patients from 2007 to 2011 in order to 
provide data consistency with a homogenous cohort of patients. Group B constitutes therefore a solid 
comparison group. The statistical analyses with the multiple logistic regression model and Cox 
proportional hazards model also reduces some bias. This retrospective analysis does not give 
evidence of the benefit of a second surgery, because it cannot prove, whether a patient lived longer 
[11] 
due to surgery or to systemic treatment or both, or whether it was natural course. Prospective 
randomized trials to validate repeated surgery and postoperative treatment modality in patients with 
glioblastoma at time of progression are still lacking 2, 17.   
 
Conclusion 
To our knowledge this is the first study on the influence of surgery combined with postoperative 
systemic therapy at time of progression in patients with recurrent glioblastoma. Furthermore, it 
represents the first attempt of validation and refinement of the existing NIH recurrent glioblastoma 
scale. The retrospective evaluation of the impact on OS of repeated surgery is difficult. Nevertheless, 
in patients that are eligible for a second resection surgery this study defines prognostic criteria of OS, 
which may be useful when counseling patients. To date, the benefit of reoperation has not been 
proven prospectively and no widely recognized criteria for treatment recommendations at 
progression exist. Although ethical concerns are often mentioned, a prospective, randomized, 
controlled trial with this issue may be inevitable. 
 
 
 
 
 
 
 
 
 
[12] 
Figures 
Fig. 1. Graphical description of patient stratification into two groups (A and B), based on treatment 
decision at time of progression. 
 
Fig. 2. Kaplan-Meier plots (abscissa = time period starts at second surgery) of patients with second 
surgery divided according to the NIH recurrent glioblastoma scale (A1 and A2) and to the adapted NIH 
recurrent glioblastoma scale (B1 and B2). The proposed updated scale includes age as an additional 
variable, nearby tumor involvement of eloquent brain regions, compromised functional status and 
tumor volume. 
[13] 
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[17] 
Tables 
 
Table 1. NIH recurrent glioblastoma scale and adapted scale: Preoperative risk assessment in progressive 
glioblastoma patients 
 
NIH Score Prognostic Group Modified NIH Score Prognostic Group 
0 Good 0 Good 
1-2 Intermediate 1-2 Intermediate 
3 Poor ≥ 3* Poor 
Additive scale, 1 point for: 
Number of critical brain regions ≥ 2; 
KPS ≤ 80; 
Tumor volume ≥ 50 cm3; 
Additive scale, 1 point for: 
Age ≥ 50 years; 
number of critical brain regions ≥ 2; 
KPS ≤ 80; 
2 points for: 
Tumor volume ≥ 50 cm3; 
* If ≥ 3 correlates with poor prognosis need of further validation because in our dataset patients with a 
score of ≥ 3 are lacking. 
Abbreviation: KPS, Karnofsky performance status. 
  
Table 2. Baseline demographic and clinical characteristics of glioblastoma patients at at first surgery 
[brackets () = %] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Only patients older than 65 years. 
  Group A 
1st surgery 
Group B 
 
p-value 
Number  40 58  
Gender male / 
female 
 29 / 11 35 / 23  
Overall survival  median 18.86 14.82 0.001 
Age median 55.04 62.63 0.004 
KPS (preoperative) median 80 80  
Corticosteroid use at 
admission 
 14 (35) 21 (36) 0.441 
Seizures  27 (68) 29 (50)  
Side of tumor 
location 
right 
left 
bilateral 
22 (55) 
18 (45) 
0 (0) 
26 (44.8) 
28 (48.3) 
4 ( 6.9) 
 
Predominant lobe of 
tumor location 
frontal 
temporal 
parietal 
occipital 
11 (27,5) 
13 (32.5) 
6 (15) 
2 (5) 
22 (37.9) 
22 (37.9) 
10 (17.2) 
1 (1.7) 
 
Eloquent regions 
involved 
0 
1 
2 
3 
31 (77.5) 
9 (22.5) 
0 (0) 
0 (0) 
44 (75.9) 
12 (20.7) 
2 (3.4) 
0 (0) 
 
MGMT promoter 
methylation 
hypermethyl. 
negative 
NA 
7 (17.5) 
15 (37.5) 
18 (45) 
10 (17.2) 
20 (34.5) 
28 (48.3) 
 
Tumor volume, cm3 median 17.44 21.5 0.377 
IDH 1 status positive 
negative 
NA 
2 (5) 
38 (95) 
0 (0) 
0 (0) 
18 (31) 
40 (69) 
 
Type of primary 
surgery 
GTR 
STR 
biopsy 
30 (75) 
10 (25) 
0 (0) 
39 (67.2) 
14 (24.2) 
5 (8.6) 
 
Complications of 1st 
surgery 
 6 (15) 5 (8.6)  
Radiotherapy part RT 60 gy 
with 
concomitant 
TMZ 
part RT 40 gy 
* without 
TMZ 
38 (95) 
 
 
 
2 (5) 
45 (77.6) 
 
 
 
13 (12.4) 
 
Treatment at 
progression 
TMZ / CCNU 
bevacizumab 
no 
10 (25) 
28 (70) 
2 (5) 
9 (22.5) 
38 (65.5) 
11 (19.0) 
 
Number of TMZ 
cycles 
median 5 3 0.00 
     
  
Abbreviation: CCNU, lomustine; IDH1, isocitrate dehydrogenase 1; KPS, Karnofsky performance status; MGMT: O6-
methylguanine-DNA-methyltransferase promoter; RT: radiotherapy; TMZ: temozolomide. 
 
Table 3. Logistic regression model (dependent variable recurrent resection) 
 
Abbreviation: KPS, Karnofsky performance status. 
 
 
 
 
Variables Odds ratio 95% confidence interval p-value 
Age at diagnosis 0.944 0.902-0.987 0.012 
Tumor volume (1st surgery) 0.997 0.983-1.011 0.661 
Preoperative KPS (1st surgery) 1.006 0.977-1.036 0.688 
Time between diagnosis and progression 1.014 0.949-1.084 0.691 
